These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17723212)

  • 1. The expanding universe of regulatory T cell subsets in cancer.
    Gajewski TF
    Immunity; 2007 Aug; 27(2):185-7. PubMed ID: 17723212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.
    Peng G; Wang HY; Peng W; Kiniwa Y; Seo KH; Wang RF
    Immunity; 2007 Aug; 27(2):334-48. PubMed ID: 17656116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
    Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
    Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of Treg cells in defective tumor immunity.
    Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
    Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors.
    Leon K; Garcia K; Carneiro J; Lage A
    J Theor Biol; 2007 Jul; 247(1):122-37. PubMed ID: 17412365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific regulatory T cells in cancer patients.
    Piersma SJ; Welters MJ; van der Burg SH
    Hum Immunol; 2008; 69(4-5):241-9. PubMed ID: 18486758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
    Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
    Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gammadelta T cell receptors without a job.
    Kapsenberg ML
    Immunity; 2009 Aug; 31(2):181-3. PubMed ID: 19699169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell subsets and colorectal cancer: discerning the good from the bad.
    Scurr M; Gallimore A; Godkin A
    Cell Immunol; 2012 Sep; 279(1):21-4. PubMed ID: 23041206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gammadelta T cells recognize tumor cells via CDR3delta region.
    Xu C; Zhang H; Hu H; He H; Wang Z; Xu Y; Chen H; Cao W; Zhang S; Cui L; Ba D; He W
    Mol Immunol; 2007 Jan; 44(4):302-10. PubMed ID: 16650897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.
    Lin YC; Chang LY; Huang CT; Peng HM; Dutta A; Chen TC; Yeh CT; Lin CY
    J Immunol; 2009 May; 182(10):6095-104. PubMed ID: 19414761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
    Wang RF
    Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple roles for CD4+ T cells in anti-tumor immune responses.
    Kennedy R; Celis E
    Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gammadelta T cell selection: is anyone useless?
    Bonneville M
    Immunity; 2008 Jul; 29(1):3-5. PubMed ID: 18631449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the prognostic value of regulatory T cells in patients with cancer.
    Badoual C; Hans S; Fridman WH; Brasnu D; Erdman S; Tartour E
    J Clin Oncol; 2009 Jul; 27(19):e5-6; author reply e7. PubMed ID: 19470910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.